THE IMPORTANCE OF METHYLTHIO-IMP FOR METHYLMERCAPTOPURINE RIBONUCLEOSIDE (ME-MPR) CYTOTOXICITY IN MOLT-F4 HUMAN-MALIGNANT T-LYMPHOBLASTS

被引:56
作者
VOGT, MHJ [1 ]
STET, EH [1 ]
DEABREU, RA [1 ]
BOKKERINK, JPM [1 ]
LAMBOOY, LHJ [1 ]
TRIJBELS, FJM [1 ]
机构
[1] CATHOLIC UNIV NIJMEGEN, ST RADBOUD HOSP, CTR PEDIAT ONCOL SE NETHERLANDS, DEPT PEDIAT, 6500 HB NIJMEGEN, NETHERLANDS
关键词
METHYLMERCAPTOPURINE RIBONUCLEOSIDE; 6-MERCAPTOPURINE; 5-PHOSPHORIBOSYL-1-PYROPHOSPHATE; PURINE DENOVO SYNTHESIS; LYMPHOBLASTIC LEUKEMIA; CYTOTOXICITY;
D O I
10.1016/0925-4439(93)90110-M
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The importance of methyl-thioIMP (Me-tIMP) formation for methylmercaptopurine ribonucleoside (Me-MPR) cytotoxicity was studied in Molt F4 cells. Cytotoxicity of Me-MPR is caused by Me-tIMP formation with concomitant inhibition of purine de novo synthesis. Inhibition of purine de novo synthesis resulted in decreased purine nucleotide levels and enhanced 5-phosphoribosyl-1-pyrophosphate (PRPP) levels, with concurrent increased pyrimidine nucleotide levels. The Me-tIMP concentration increased proportionally with the concentration of Me-MPR. High Me-tIMP concentration also caused inhibition of PRPP synthesis. Maximal accumulation of PRPP thus occurred at low Me-MPR concentrations. As little as 0.2 muM Me-MPR resulted already after 2 h in maximal inhibition of formation of adenine and guanine nucleotides, caused by inhibition of purine de novo synthesis by Me-tIMP. Under these circumstances increased intracellular PRPP concentrations could be demonstrated, resulting in increased levels of pyrimidine nucleotides. So, in Molt F4 cells, formation of Me-tIMP from Me-MPR results in cytotoxicity by inhibition of purine de novo synthesis.
引用
收藏
页码:189 / 194
页数:6
相关论文
共 37 条
[1]  
BENNETT LL, 1971, CANCER RES, V31, P152
[2]   REVERSAL OF GROWTH INHIBITORY EFFECTS OF 6-METHYLTHIOPURINE RIBONUCLEOSIDE [J].
BENNETT, LL ;
ADAMSON, DJ .
BIOCHEMICAL PHARMACOLOGY, 1970, 19 (06) :2172-&
[3]   ACTIVITY AND MECHANISM OF ACTION OF 6-METHYLTHIOPURINE RIBONUCLEOSIDE IN CANCER CELLS RESISTANT TO 6-MERCAPTOPURINE [J].
BENNETT, LL ;
BROCKMAN, RW ;
SCHNEBLI, HP ;
CHUMLEY, S ;
DIXON, GJ ;
SCHABEL, FM ;
DULMADGE, EA ;
SKIPPER, HE ;
MONTGOMERY, JA ;
THOMAS, HJ .
NATURE, 1965, 205 (4978) :1276-+
[4]   SEQUENCE-DEPENDENT, TIME-DEPENDENT AND DOSE-DEPENDENT SYNERGISM OF METHOTREXATE AND 6-MERCAPTOPURINE IN MALIGNANT HUMAN T-LYMPHOBLASTS [J].
BOKKERINK, JPM ;
BAKKER, MAH ;
HULSCHER, TW ;
DEABREU, RRA ;
SCHRETLEN, EDAM ;
VANLAARHOVEN, JPRM ;
DEBRUYN, CHMM .
BIOCHEMICAL PHARMACOLOGY, 1986, 35 (20) :3549-3555
[5]  
BOKKERINK JPM, 1992, BIOCH PHARM
[6]  
BROCKMAN RW, 1963, CANCER RES, V23, P1191
[7]   ENZYMIC FORMATION OF 6-(METHYLMERCAPTO)PURINE RIBONUCLEOSIDE 5'-PHOSPHATE [J].
CALDWELL, IC ;
HENDERSON, JF ;
PATERSON, AR .
CANADIAN JOURNAL OF BIOCHEMISTRY, 1966, 44 (02) :229-+
[8]   THE IMPORTANCE OF THIOPURINE METHYLTRANSFERASE ACTIVITY FOR THE USE OF AZATHIOPRINE IN TRANSPLANT RECIPIENTS [J].
CHOCAIR, PR ;
DULEY, JA ;
SIMMONDS, HA ;
CAMERON, JS .
TRANSPLANTATION, 1992, 53 (05) :1051-1056
[9]   HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAY FOR IDENTIFICATION AND QUANTITATION OF NUCLEOTIDES IN LYMPHOCYTES AND MALIGNANT LYMPHOBLASTS [J].
DEABREU, RA ;
VANBAAL, JM ;
BAKKEREN, JAJM ;
DEBRUYN, CHMM ;
SCHRETLEN, EDAM .
JOURNAL OF CHROMATOGRAPHY, 1982, 227 (01) :45-52
[10]  
ELION GB, 1967, FED PROC, V26, P898